Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Deals

Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform

Fineline Cube Aug 22, 2025

On August 22, 2025, Kite Pharma, Inc., a subsidiary of Gilead Sciences (NASDAQ: GILD), announced...

Company Drug

Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention

Fineline Cube Aug 22, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on August 22, 2025, that the U.S. Food and...

Company Drug Policy / Regulatory

InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors

Fineline Cube Aug 22, 2025

China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...

Company Medical Device

Lifetech Scientific’s PDA Occluder Gains NMPA Innovative Device Review Status

Fineline Cube Aug 22, 2025

On August 22, 2025, China-based Lifetech Scientific Corporation (HKG: 1302) announced that its nitinol patent...

Company Deals

Bio-Thera Inks EUR 136m Deal with STADA for BAT1806 Commercialization

Fineline Cube Aug 21, 2025

On August 21, 2025, Bio-Thera Solutions, Ltd. (SHA: 688177) announced a license and commercialization agreement...

Company Deals

3D Medicines and CATUG Biotech Forge Strategic Alliance in mRNA-LNP Innovation

Fineline Cube Aug 21, 2025

China-based 3D Medicines (HKG: 1244) has entered into a strategic cooperation framework agreement with CATUG Biotechnology....

Company Drug

Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards

Fineline Cube Aug 21, 2025

On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...

Company Drug

Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction

Fineline Cube Aug 21, 2025

Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors

Fineline Cube Aug 21, 2025

On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...

Others

Minova’s MI078 Shows Promising Results in Postpartum Depression Trial

Fineline Cube Aug 21, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd. has announced positive results from a Phase 2 clinical trial...

Company Deals

Abbisko’s ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist

Fineline Cube Aug 21, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that the Center for Drug Evaluation...

Company Drug

Sino Biopharma’s Zongertinib Receives Second Breakthrough Designation for NSCLC

Fineline Cube Aug 21, 2025

On August 20, 2025, Sino Biopharmaceutical Limited (HKG: 1177) announced that its selective HER2 tyrosine...

Company Deals Medical Device

Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition

Fineline Cube Aug 21, 2025

Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its...

Company Deals

Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA

Fineline Cube Aug 21, 2025

On August 21, 2025, Nanjing Zenshine Pharmaceuticals Co., Ltd, a China-based developer of small molecule...

Policy / Regulatory

China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals

Fineline Cube Aug 21, 2025

On August 20, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products...

Company

Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales

Fineline Cube Aug 21, 2025

China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half...

Company Drug

Chongqing Genrix Bio Pharmaceutical’s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents

Fineline Cube Aug 20, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802...

Company Deals

Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East

Fineline Cube Aug 20, 2025

Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has...

Company Deals

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform

Fineline Cube Aug 20, 2025

Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by...

Policy / Regulatory

China Unveils Ten Measures to Boost Family Doctor Contract Services

Fineline Cube Aug 20, 2025

In a significant move to enhance the quality and accessibility of primary healthcare, the National...

Posts pagination

1 … 157 158 159 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.